Emergent BioSolutions Inc
For the period ended Dec 31, 2024. Filed Mar 4, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 4, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 9B. Other Information
During the three months ended December 31, 2024, directors and officers (as defined in Exchange Act Rule 16a-1(f)) of the Company adopted written plans for the sale of the Company’s common stock intended to satisfy the affirmative defense conditions of Exchange Act Rule 10b5-1(c) (“Rule 10b5-1 trading arrangements”) as set forth in the table below.
| Name | Position | Action | Adoption date | Rule 10b5-1 Trading Plan Provides for Purchase/Sale (1) | Total Shares of Common Stock to be Sold | Expiration Date (2) |
|---|---|---|---|---|---|---|
| Keith Katkin | Director | Adoption | November 8, 2024 | Sale | 7,844 | November 8, 2025 |
| Coleen Glessner | Chief Quality and Compliance Officer | Adoption | December 2, 2024 | Sale | 30,608 | December 31, 2025 |
| (2) Subject to early termination in accordance with the terms of the Rule 10b5-1 trading arrangements. | ||||||
Each of the above-named directors and officers is currently and is expected to remain in compliance with his or her share ownership guidelines following the sale of any common shares pursuant to his or her Rule 10b5-1 trading arrangement.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.